Status:
RECRUITING
The Effect of Compensation Strategies on Gait Impairment in Parkinson's Disease
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
KU Leuven
Tel-Aviv Sourasky Medical Center
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Gait disturbances are disabling and common in Parkinson's disease (PD). Patients use many different, and typically self-developed, strategies to compensate for their walking abnormalities. There is a ...
Eligibility Criteria
Inclusion
- Men and women of age \> 18 years with idiopathic Parkinson's disease;
- Written informed consent.
Exclusion
- Daily usage of compensation strategies for the past month;
- Presence of deep brain stimulation (DBS);
- Presence of severe co-morbidity limiting ambulation (e.g. stroke, orthopaedic problems);
- Inability to walk unaided (with the exception of a customary cane);
- Inability to walk for \> 3 minutes consecutively;
- Severe auditory impairments, hampering perception of auditory cues;
- Severe cognitive impairment (MMSE \< 21)
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
384 Patients enrolled
Trial Details
Trial ID
NCT06142448
Start Date
December 1 2023
End Date
December 1 2026
Last Update
July 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboudumc
Nijmegen, Netherlands